A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning.

Official record

Identifier

NCT07669727

Recruiting locations

Locations are not included in the offline baseline for this record. Open the official record to see the current site list.

Interventions studied

TheraSphere

Lead sponsor

Boston Scientific Corporation

Target enrolment

140 participants

Study type

OBSERVATIONAL

Phase

Not provided in the official record

Status

Not yet recruiting

First posted

Jun 25, 2026

Last updated on the registry

Oct 1, 2026

Age

18 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

* TheraSphere Microspheres treatment determined as the optimal therapy
* Have unresectable solitary HCC
* Treatment Naïve
* ECOG 0 or 1
* Adequate liver function
* Adequate renal and marrow function
* Negative pregnancy test and/or adequate contraception for the patient and his/her sexual partner

Exclusion Criteria:

* Macrovascular invasion
* Extrahepatic metastases
* Previous or current ascites/encephalopathy
* Previous liver radiation, TACE, or systemic therapy for the disease
* History of organ allograft including bone marrow
* Any significant comorbities or contraindications to TheraSphere

Indexed under

Liver Cancer